Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

AIMS: To examine 12-month outcomes of eyes switching from intravitreal ranibizumab to aflibercept for neovascular age-related macular degeneration (nAMD). METHODS: Database observational study of eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that received ranibizumab for at...

Descripción completa

Detalles Bibliográficos
Autores principales: Barthelmes, Daniel, Campain, Anna, Nguyen, Phuc, Arnold, Jennifer J, McAllister, Ian L, Simpson, Judy M, Hunyor, Alex P, Guymer, Robyn, Essex, Rohan W, Morlet, Nigel, Gillies, Mark C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256411/
https://www.ncbi.nlm.nih.gov/pubmed/26994110
http://dx.doi.org/10.1136/bjophthalmol-2015-308090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256411/
https://www.ncbi.nlm.nih.gov/pubmed/26994110
http://dx.doi.org/10.1136/bjophthalmol-2015-308090

Ejemplares similares